Coronavirus: Please see here for our latest COVID-19 advice for our patients and their relatives.
Our thoracic oncology research team celebrated a big milestone this week, with the 500th participant recruited to the LuCID study.
The Lung Cancer Indicator Detection (LuCID) study is examining whether exhaled breath can be used to diagnose lung cancer at an earlier stage.
The first Royal Papworth patient joined the study in January 2016, and people will continue to be recruited until the end of 2020.
The 500 Royal Papworth participants are part of 2,300 across Europe, with capacity to recruit up to 4,000.
Robert Rintoul, Chief Investigator for the LuCID study, said: “This is a fantastic achievement by the team, with Royal Papworth now accounting for more than a fifth of the total recruits.
“We know that patients diagnosed at stage one lung cancer have an approximately 80% chance of living for more than five years, whereas at stage four this is just 1%.
“Working in conjunction with Owlstone Medical, this trial could therefore help to improve outcomes for patients in the future.”